Key facts
- Developer of a biocatalyst engineering technology designed to repurpose enzymes to create a new compound.
- Aether Bio’s last known valuation is $110.0M (Dec 2025).
- It has raised $73.9M; the latest was Later Stage VC ($15.0M) in Dec 2025.
- Notable investors include Gaingels, BoxGroup, Calm Ventures, Abstract Ventures, Tribe Capital — 28 tracked in total.
- Status: Privately Held (backing).
Leadership
- Jay ZaveriFounder & President
- ·The complete investor list — 28 names
- ·Watchlist + deal alerts for Aether Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Aether Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aether Bio
Developer of a biocatalyst engineering technology designed to repurpose enzymes to create a new compound. The company's technology utilizes machine learning combined with high-throughput robotic laboratories to engineer enzymes rapidly and allows massively parallelized experimentation, generating datasets orders of magnitude larger, enabling researchers to manufacture complex and novel medical products at a fraction cost.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2017
- Employees
- 38
- Website
- aetherbio.com/
- Ownership
- Privately Held (backing)
Aether Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.